Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1% metformin gel is a locally-delivered, biodegradable, controlled-release formulation developed by researchers at the Government Dental College and Research Institute in Bangalore, India. While metformin is traditionally an oral biguanide used for type 2 diabetes, this specific formulation is designed for subgingival application as an adjunct to scaling and root planing (SRP) in the treatment of chronic periodontitis and intrabony periodontal defects. The drug exerts its therapeutic effect by promoting osteoblast proliferation and differentiation, leading to bone-sparing effects and the regeneration of alveolar bone within periodontal pockets. Clinical trials have demonstrated significant improvements in clinical parameters such as probing depth reduction, clinical attachment level gain, and bone defect fill compared to scaling and root planing alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1% metformin gel.